Fears of regulatory hurdles for new manufacturing platforms may be overstated. Regulators, familiar with technologies like molecular farming for decades, prioritize the final product's purity, safety, and efficacy. The platform's novelty is secondary to robust scientific data proving the end product's quality.

Companies developing therapies with novel components like membrane proteins must navigate CMC development without established regulatory guidance. Unlike well-understood biologics like monoclonal antibodies, the lack of precedent in databases creates unique challenges for defining processes and satisfying regulatory bodies, requiring pioneers to set the standards.

The FDA receives raw and cleaned datasets from sponsors, not just summary reports. Their internal teams conduct independent analyses, which can lead to findings or data presentations in the official drug label that differ from or expand upon what's in the published paper.

For early-stage biotech companies, saving money by limiting initial drug substance characterization is a false economy. A comprehensive, state-of-the-art characterization before Phase 1 is essential to de-risk the program by identifying molecular issues before they become catastrophic problems in late-stage development.

Pharma teams often fear changing formulations late in development due to perceived regulatory hurdles. However, the path, which involves a relative bioavailability study to bridge the old and new formulations, is a well-established and manageable process if key safety and efficacy metrics are maintained.

When developing a novel platform with no regulatory precedent, the key is to present a robust scientific case to agencies. This involves educating them with comprehensive data and explaining the 'why' behind your approach, rather than simply trying to fit into existing guidelines that may not apply.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

Understanding whether a product's primary function is physical (medical device) or pharmacological (drug) is a critical first step for founders. This self-classification, validated early with experts, dictates the entire regulatory framework, saving significant time and resources.

Teams focus on clinical data for accelerated FDA designations but often underestimate the reality that this forces an equally accelerated timeline for Chemistry, Manufacturing, and Controls (CMC). Manufacturing scale-up, validation, and analytical testing must keep pace with the clinical program to avoid significant delays.